SEATTLE, Nov. 7, 2014 (GLOBE NEWSWIRE) -- NanoString Technologies, Inc. (Nasdaq:NSTG), a provider of life science translational research and molecular diagnostic products, today announced that its management is scheduled to present at the Canaccord Genuity Medical Technology and Diagnostics Forum in New York City.
Brad Gray, President and Chief Executive Officer, is scheduled to present on Thursday, November 20, 2014 at 11:00 am ET. Interested parties can access the live webcast with accompanying slides from the investor section of the company's website at www.nanostring.com. The webcast replay will be available one hour after the conclusion of the live presentation and archived for 90 days.
About NanoString Technologies, Inc.
NanoString Technologies provides life science tools for translational research and molecular diagnostic products. The company's nCounter Analysis System has been employed in life sciences research since it was first introduced in 2008 and has been cited in hundreds of peer-reviewed publications. The nCounter Analysis System offers a cost-effective way to easily profile the expression of hundreds of genes, miRNAs, or copy number variations, simultaneously with high sensitivity and precision, facilitating a wide variety of basic research and translational medicine applications, including biomarker discovery and validation. The company's technology has now been applied to diagnostic use. The Prosigna Breast Cancer Prognostic Gene Signature Assay together with the nCounter Dx Analysis System is FDA 510(k) cleared for use as a prognostic indicator for distant recurrence of breast cancer.
For more information, please visit www.nanostring.com.
The NanoString Technologies logo, NanoString, NanoString Technologies, nCounter, and Prosigna are registered trademarks or trademarks of NanoString Technologies, Inc. in various jurisdictions.
CONTACT: Investor Contact: Leigh Salvo of Westwicke Partners For NanoString Technologies firstname.lastname@example.org 415-513-1281
Source:NanoString Technologies, Inc.